IACH News Podcasts

Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.

April 20th- Beyond the webinar: Non-Transfusion-Dependent Thalassemia: From Observation to Intervention

CME Congresses .

April 20th- Beyond the webinar: Non-Transfusion-Dependent Thalassemia: From Observation to Intervention

April 13th- Dr. Florian Simon- Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

CME Congresses .

April 13th- Dr. Florian Simon- Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

April 9th- Beyond the Webinar: EBMT 2026- From Innovation to Clinical Impact

CME Congresses .

April 9th- Beyond the Webinar: EBMT 2026- From Innovation to Clinical Impact

April 7th- Beyond the Webinar: Menin Inhibitors in AML – From Biology to Clinical Impact

CME Congresses .

April 7th- Beyond the Webinar: Menin Inhibitors in AML – From Biology to Clinical Impact

April 6th- Access to Therapy in Multiple Myeloma: From Innovation to Equity

CME Congresses .

April 6th- Access to Therapy in Multiple Myeloma: From Innovation to Equity

March 30th- Dr. Andres Ramirez Gamero- Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia

CME Congresses .

March 30th- Dr. Andres Ramirez Gamero- Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia

March 23rd- Zanubrutinib in High-Risk CLL: Changing the Prognosis of del(17p)/TP53 Disease

CME Congresses .

March 23rd- Zanubrutinib in High-Risk CLL: Changing the Prognosis of del(17p)/TP53 Disease

March 19th- Beyond the webinar: CAR-T Cell Therapy: Are We Entering a New Therapeutic Era?

CME Congresses .

March 19th- Beyond the webinar: CAR-T Cell Therapy: Are We Entering a New Therapeutic Era?

March 17th- Beyond the webinar: CARTITUDE-4 long-term follow-up: Is early CAR-T changing the natural history of relapsed myeloma?

CME Congresses .

March 17th- Beyond the webinar: CARTITUDE-4 long-term follow-up: Is early CAR-T changing the natural history of relapsed myeloma?

March 16th- Belumosudil vs Best Available Therapy in cGVHD: Real-World Evidence That Matters

CME Congresses .

March 16th- Belumosudil vs Best Available Therapy in cGVHD: Real-World Evidence That Matters